shutterstock_1349493995_ministocker
MiniStocker / Shutterstock.com
2 March 2021BiotechnologyAlex Baldwin

Five minutes with… Eva Kabir

Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
25 February 2021   Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
article
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More on this story

Biotechnology
25 February 2021   Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
article
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More on this story

Biotechnology
25 February 2021   Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
article
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.